GeneDx Holdings Corp. (NASDAQ:WGS) - Craig-Hallum Reaffirms Buy Rating with $153 Price Target

Craig-Hallum has reaffirmed its Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) with a $153 price target, citing data presented at the ACMG Annual Meeting that shows the company's testing reduces healthcare resource utilization and costs. Analysts remain bullish despite a 9% decline in shares following a competitor's launch. BTIG has also maintained a Buy rating with a $170 price target. GeneDx is a leader in rare disease genomics and exome/genome sequencing.